Lattice Biologics Ltd.

30 articles about Lattice Biologics Ltd.

• Lattice Biologics Ltd. Reports Second Quarter 2021 Results and Resumes Trading

  7/9/2021

  All existing inventory processed by Lattice Biologics Inc., or under private label, is safe to use until the expiration date and remains in full compliance with all regulatory bodies.

• Lattice Announces Strategic Advisory Board

  3/31/2021

  Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“Lattice” or the “Company”), an emerging leader in psilocybin research and cannabis company, today announced the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Lattice’s executive team as it continues to build and strengthen the Company's portfolio of cannabis and psilocybin related brands and products

• Lattice Biologics Ltd. Reports First Quarter 2021 Highlights

  3/1/2021

  Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“ Lattice Biologics ” or the “ Company ”) announces financial results for Q1 2021. Highlights of Three Months Ended December 31, 2020 Sales and Product Offerings Gross profit margin was 48.1% for the three months ended December 31, 2020, compared to 57.1% for the same period in the previous year.

•  Lattice Biologics Ltd. Reports Fourth Quarter and Year End 2020 Highlights

  1/29/2021

  Lattice Biologics Ltd. announces financial results for Q4 2020 and year end 2020.

• Lattice Unaware of Any Material Change

  1/6/2021

  Lattice Biologics Ltd. at the request of the Investment Industry Regulatory Organization of Canada, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and trading volume of its common shares.

• COVID19 UPDATE – Lattice Biologics Announces Cessation of Patient Recruitment

  9/3/2020

  The study was designed to evaluate the efficacy and safety of AmnioBoost in patients with acute respiratory distress syndrome due to COVID19.

• Lattice Biologics Issues Shares and Warrants

  8/18/2020

  Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) has issued common shares and warrants pursuant to a litigation settlement. Pursuant to the litigation settlement Ms. Cheryl Farmer acquired 18,000,000 common shares of the Company representing 17.2% of the issued and outstanding common shares of the Company and 500,000 warrants of the Company. The common shares are subject to a

• Lattice Biologics Eliminates CAN$838,000 in Debt

  6/8/2020

  Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has obtained TSX-V approval to issue 16,760,000 common shares of the Company to settle outstanding debt.

• Lattice Biologics Ltd. Reports Second Quarter 2020 Results

  6/2/2020

  Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“ Lattice Biologics ” or the “ Company ”) announces financial results for Q2 2020 Highlights of the Three and Six Months Ended March 31, 2020 Sales and Product Offerings Gross profit margin was 56% for the three months ended March 31, 2020, compared to 77% for the same period in the previous year. Gross profit margin was 57% for the six

• Lattice Biologics Ltd. Announces Option Repricing

  4/15/2020

  Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“ Lattice Biologics ” or the “ Company ”) announces that the Company has repriced the strike price of the 3 million stock options originally to be granted to Directors and Employees announced on March 16, 2020 to $.095 from $.075 due to recent market activity. The options will have an exercise term of five years from the date of grant. Subscribe to Lattic

• Lattice Biologics Signs Definitive Agreement with Alumina Partners for $6 Million At-Will Offering Facility

  4/7/2020

  Lattice Biologics Ltd. is pleased to announce that it has entered into a definitive agreement with Alumina Partners Ltd. for a commitment of up to $6,000,000 CDN in an at-will offering facility.

• Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to Access Safety and Efficacy of AmnioBoost for Treatment of COVID-19

  3/17/2020

  Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection. AmnioBoost is derived from amniotic fluid taken from non-related, healthy, living

• Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease

  3/13/2020

  Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) today announced that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19)

• Lattice Biologics Announces Planned Debt-to-Equity Conversion

  3/11/2020

  Lattice Biologics Ltd. announces that, subject to TSXV approval, the Company plans to convert US $726,200 of debt into equity of Lattice Biologics.

• LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2

  3/3/2020

  March 3, 2020 22:00 UTC LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2

• Lattice Biologics Ltd. Reports Q1 2020 Results

  2/28/2020

  Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q1 2020.

• Lattice Biologics Ltd. Reports Year End 2019 Results and Q1 Preliminary Q1 2020 Revenues

  1/29/2020

  Lattice Biologics Ltd. announces financial results for the fiscal year end 2019 and preliminary revenues for Q1 2020..

• Lattice Biologics Ltd. Reports Third Quarter 2019 Results

  8/29/2019

  Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q3 2019.

• Lattice Biologics Ltd. Reports Second Quarter 2019 Results

  5/31/2019

  Lattice Biologics Ltd. announces financial results for Q2 2019.

• Lattice Biologics Ltd. Reports Year End 2018 Results

  1/29/2019

  Successfully relocated processing facility to Belgrade, Montana, resulting in reduced overhead and increased operational efficiencies.